Compare SRRK & ENVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRRK | ENVA |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 5.8B |
| IPO Year | 2018 | 2011 |
| Metric | SRRK | ENVA |
|---|---|---|
| Price | $47.76 | $235.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | $56.17 | ★ $185.71 |
| AVG Volume (30 Days) | ★ 1.2M | 382.4K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.05 |
| EPS | N/A | ★ 7.45 |
| Revenue | N/A | ★ $3,151,653,000.00 |
| Revenue This Year | N/A | $149.64 |
| Revenue Next Year | $534.24 | $16.42 |
| P/E Ratio | ★ N/A | $62.95 |
| Revenue Growth | N/A | ★ 18.58 |
| 52 Week Low | $27.07 | $99.61 |
| 52 Week High | $58.49 | $246.38 |
| Indicator | SRRK | ENVA |
|---|---|---|
| Relative Strength Index (RSI) | 39.63 | 61.43 |
| Support Level | $45.46 | $220.13 |
| Resistance Level | $48.23 | $246.38 |
| Average True Range (ATR) | 2.44 | 8.73 |
| MACD | -1.01 | -3.01 |
| Stochastic Oscillator | 6.24 | 78.13 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Enova International Inc provides online financial services, including short-term consumer loans, line of credit accounts, and installment loans to customers mainly in the United States and Brazil. Consumers apply for credit online, the company's technology platforms process the applications, and transactions are completed quickly and efficiently. Its customers are predominantly retail consumers and small businesses. Enova markets its financing products under the names CashNetUSA, NetCredit, OnDeck, Headway Capital, and Simplic. The company also operates a money transfer platform under the name Pangea. Geographically, the company generates a majority of its revenue from its business in the United States and the rest from other international countries.